News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Category: Press Releases

Epigenomics Initiates prospective multi-center clinical trial for “Next-Generation” blood-based colorectal cancer test

EQS-News: Epigenomics AG / Key word(s): StudyEpigenomics Initiates prospective multi-center clinical trial for “Next-Generation” blood-based colorectal cancer test 19.09.2022 / 07:00 CET/CESTThe issuer is solely responsible for the content of this announcement. Epigenomics Initiates prospective multi-center clinical trial for “Next-Generation” blood-based colorectal cancer test First subject has been enrolled in the Company’s CRC-DRAW trial Data […]

Read more

Epigenomics AG: Notice of Loss pursuant to Sec. 92 par. 1 AktG

DGAP-News: Epigenomics AG / Key word(s): Miscellaneous/AGM/EGMEpigenomics AG: Notice of Loss pursuant to Sec. 92 par. 1 AktG 15.08.2022 / 09:00 CET/CESTThe issuer is solely responsible for the content of this announcement. Epigenomics AG: Notice of Loss pursuant to Sec. 92 par. 1 AktG Berlin, August 15, 2022 – The Executive Board of Epigenomics AG […]

Read more

​​​​​​​Epigenomics AG Reports Financial Results for the First Six Months of 2022

DGAP-News: Epigenomics AG / Key word(s): Half Year Report/Half Year Results​​​​​​​Epigenomics AG Reports Financial Results for the First Six Months of 2022 10.08.2022 / 08:00 CET/CESTThe issuer is solely responsible for the content of this announcement. Epigenomics AG Reports Financial Results for the First Six Months of 2022 Berlin (Germany) and San Diego, CA (U.S.A.), […]

Read more

Epigenomics AG Reports Financial Results for the First Quarter of 2022

DGAP-News: Epigenomics AG / Key word(s): Quarterly / Interim Statement/Quarter ResultsEpigenomics AG Reports Financial Results for the First Quarter of 2022 11.05.2022 / 08:00 The issuer is solely responsible for the content of this announcement. Epigenomics AG Reports Financial Results for the First Quarter of 2022 Berlin (Germany) and San Diego, CA (U.S.A.), May 11, […]

Read more

​​​​​​​Epigenomics AG Reports Financial Results for Fiscal Year 2021

DGAP-News: Epigenomics AG / Key word(s): Annual Report/Annual Results24.03.2022 / 08:00 The issuer is solely responsible for the content of this announcement. Epigenomics AG Reports Financial Results for Fiscal Year 2021 Total revenue of EUR 6.2 million, adjusted EBITDA of EUR -1.8 million FDA clinical trial for Epi proColon “Next Gen” expected to start with […]

Read more

Supervisory Board of Epigenomics AG Retains Greg Hamilton as Chief Executive Officer Through Development of Epi proColon ‘Next-Gen’ Colorectal Cancer Screening Test

DGAP-News: Epigenomics AG / Key word(s): Personnel24.01.2022 / 07:00 The issuer is solely responsible for the content of this announcement. Supervisory Board of Epigenomics AG Retains Greg Hamilton as Chief Executive Officer Through Development of Epi proColon “Next-Gen” Colorectal Cancer Screening Test Greg Hamilton retained as CEO through 2025 Appointment underscores Epigenomics’ commitment to the […]

Read more